卫信康(603676) - 卫信康投资者关系活动记录表（2024-11-29）

Group 1: Company Overview - The company is Tibet Weixin Kang Pharmaceutical Co., Ltd., with stock code 603676 and abbreviation Weixin Kang [1][2] - The company is involved in the production of injectable multivitamins and other nutritional products [4][5] Group 2: Market Competition - Currently, there are three manufacturers in the injectable multivitamins (12) market, with one more under application [4] - The competitive landscape for composite vitamin products has remained stable in recent years [4] Group 3: Financial Performance - The sales revenue for pediatric multivitamin injection (13) reached CNY 32.75 million in the first half of 2024, a year-on-year increase of 47.29% [5] - The company has successfully controlled costs despite price reductions following centralized procurement [4][6] Group 4: Product Development - The company is expanding its product matrix with the approval of multiple trace element injections, targeting both adult and pediatric patients [6] - The company is closely monitoring the market for potential opportunities and challenges, particularly in the context of price governance policies [6] Group 5: Share Buyback - As of November 25, 2024, the company has repurchased 156,700 shares, accounting for 0.036% of the total share capital, with a total transaction amount of CNY 1,541,919 [6]